A Phase 4 Randomized OpenLabel Trial to Describe the Safety Tolerability and Immunogenicity of 13 Valent Pneumococcal Conjugate Vaccine Formulated in Multidose Vials When Given With Routine Pediatric Vaccines in Healthy Infants in India.
Latest Information Update: 22 Oct 2021
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 13 Oct 2021 Results published in the Vaccine
- 20 Feb 2020 Status changed from active, no longer recruiting to completed.
- 25 Feb 2019 Planned End Date changed from 3 Feb 2020 to 1 Dec 2019.